Flex Pharma, Inc. (FLKS) financial statements (2021 and earlier)

Company profile

Business Address 2450 HOLCOMBE BLVD
HOUSTON, TX 77021
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1110710447
Cash and cash equivalents1110710447
Receivables4321  0
Inventory, net of allowances, customer advances and progress billings      0
Inventory      0
Prepaid expense110011 
Other current assets000000 
Other undisclosed current assets 000000
Total current assets:1614911557
Noncurrent Assets
Property, plant and equipment0000000
Intangible assets, net (including goodwill)999999 
Goodwill999999 
Other noncurrent assets000000 
Total noncurrent assets:9999990
TOTAL ASSETS:2523192014147
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2111221
Accounts payable2111221
Accrued liabilities      0
Employee-related liabilities      0
Deferred revenue    12 
Debt01 011 
Derivative instruments and hedges, liabilities000000 
Due to related parties     0 
Total current liabilities:2211341
Noncurrent Liabilities
Other undisclosed liabilities000100 
Total liabilities:3222351
Stockholders' equity
Stockholders' equity attributable to parent2221171811106
Preferred stock   0   
Common stock0000000
Additional paid in capital423833322320143
Accumulated deficit(19)(18)(16)(14)(12)(10)(137)
Total stockholders' equity:2221171811106
TOTAL LIABILITIES AND EQUITY:2523192014147

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Revenues1111110
Cost of revenue
(Cost of Goods and Services Sold)
      (0)
Gross profit:1111110
Operating expenses(3)(3)(3)(4)(3)(5)(2)
Other undisclosed operating income      0
Operating loss:(2)(2)(2)(2)(2)(4)(1)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(0) 0    
Net loss:(2)(2)(2)(2)(2)(4)(1)
Other undisclosed net income (loss) attributable to parent(0)0(0)0010
Net loss attributable to parent:(2)(2)(2)(2)(2)(3)(1)
Other undisclosed net loss available to common stockholders, basic(0)      
Net loss available to common stockholders, diluted:(2)(2)(2)(2)(2)(3)(1)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(2)(2)(2)(2)(2)(4)(1)
Comprehensive loss:(2)(2)(2)(2)(2)(4)(1)
Other undisclosed comprehensive income, net of tax, attributable to parent      0
Comprehensive loss, net of tax, attributable to parent:(2)(2)(2)(2)(2)(4)(1)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: